Patents by Inventor Tomoji Aotsuka

Tomoji Aotsuka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5532257
    Abstract: Production of a benzothiazole compound of the formula (I) ##STR1## wherein R.sup.1 is a halogen atom, R.sup.2 and R.sup.3 may be the same or different and each is a hydrogen atom or a halogen atom, R.sup.4 is a hydrogen atom, a halogen atom, a lower alkyl, an alkoxy or an alkyl mercapto and R.sup.5 is a hydrogen atom or a lower alkyl, or a pharmaceutically acceptable salt thereof.The compound of the formula (I) and a pharmaceutically acceptable salt thereof of the present invention have an aldose reductase inhibitory activity in mammals inclusive of human and have superior safety. Accordingly, they are useful as pharmaceutical compositions for the treatment of the complications of diabetes, such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, particularly cataract and neurosis.
    Type: Grant
    Filed: November 25, 1994
    Date of Patent: July 2, 1996
    Assignees: Senju Pharmaceutical Co., Ltd, The Green Cross Corporation
    Inventors: Takema Hase, Takahiro Kumonaka, Chikako Shimizu, Hiroshi Hosono, Tomoji Aotsuka, Yoshiyuki Nakamura, Tetsuo Matsui, Hiromichi Ishikawa
  • Patent number: 5252571
    Abstract: 1,4-Benzothiazine-2-acetic acid derivatives having an excellent aldose reductase inhibitory activity which are useful for the prevention and treatment of diabetic complications, such as diabetic cataract, retinopathy, nephropathy and neuropathy.
    Type: Grant
    Filed: December 24, 1991
    Date of Patent: October 12, 1993
    Assignee: Sapporo Breweries Limited
    Inventors: Tomoji Aotsuka, Hiroshi Hosono, Toshio Kurihara, Yoshiyuki Nakamura, Tetsuo Matsui, Fujio Kobayashi
  • Patent number: 5198450
    Abstract: An agent for treating or preventing cerebral circulation disorder, cerebral metabolism disorder, or memory disturbance is disclosed. The agent comprises as an effective component a phenylalkanoylamine derivative represented by the following formula (I), ##STR1## wherein A represents a 1,3-thiazolidin-3-yl group, a 1,2,3,6-tetrahydropyridin-1-yl group, a morpholino group, a thiomorpholin-4-yl group, or a 3-pyrrolin-1-yl group, R.sup.1 and R.sup.2, which may be the same or different, represent a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a nitro group, an amino group, a guanidino group, or a group ##STR2## (wherein R.sup.3 and R.sup.4 independently represent a lower alkyl group or form in combination 5- or 6-membered heterocyclic group), and n represents an integer of 2-6, or a salt thereof.
    Type: Grant
    Filed: January 7, 1991
    Date of Patent: March 30, 1993
    Assignee: Zeria Pharmaceutical Co., Ltd.
    Inventors: Kuniyoshi Ogura, Tomoji Aotsuka, Motoki Torizuka, Mitsuo Soeda, Yoshiaki Tanaka, Hisayoshi Kato, Naoyoshi Miura, Noaki Nakata, Hikaru Morita, Akihiro Okubo
  • Patent number: 5028604
    Abstract: Novel condensed benzene derivatives having prolyl endopeptidase inhibitory, anti-hypoxic, and anti-amnesic activities are disclosed. The compounds are represented by the following (I), ##STR1## wherein A represents a methylene, ethylene, or propylene group, B represents a methylene or ethylene group, m denotes an integer of 0-5, X and Y, which may be same or different, individually represent a methylene group or sulfur atom, R.sup.1 represents a hydrogen atom, a carboxyl, lower alkyloxycarbonyl, hydroxymethyl, or formyl group, R.sup.2 represents a hydrogen atom, a halogen atom, a lower alkyl, lower alkoxy, nitro, or amino group, R.sup.3 represents a hydrogen atom or a lower alkyl group, and the dotted line may optionally be present. They are useful as a medicine for treating or preventing cerebral circulation disorder, cerebral metabolism disorder, or memory disturbance.
    Type: Grant
    Filed: December 1, 1989
    Date of Patent: July 2, 1991
    Assignee: Zeria Pharmaceutical Co., Ltd.
    Inventors: Motoki Torizuka, Tomoji Aotsuka, Mitsuo Soeda, Kuniyoshi Ogura, Yoshiaki Tanaka, Hisayoshi Kato, Naoki Nakata, Naoyoshi Miura, Hikari Morita
  • Patent number: 4916146
    Abstract: Novel N-substituted amino acid imide derivatives are disclosed. The compounds are represented by formula (I): ##STR1## wherein n represents an integer of 0 to 5, and X and Y, which may be the same or different, represent a methylene group or a sulfur atom, provided that not both X and Y are methylene groups at the same time. The compounds are useful as a medicine for treating or preventing cerebral circulation disorder, cerebral metabolism disorder, or memory disturbance.
    Type: Grant
    Filed: December 22, 1988
    Date of Patent: April 10, 1990
    Assignee: Zeria Pharmaceutical Co., Ltd.
    Inventors: Yoshiaki Tanaka, Tomoji Aotsuka, Naomi Kobayashi, Naoki Nakata, Kuniyoshi Ogura, Motoki Torizuka, Naoyoshi Miura, Heihachiro Arai